SERI Lugano is involved in research and innovation in vision, focusing on advanced ophthalmic treatments and therapies for various eye conditions.

SERI Lugano

Swiss Eye Centre is an ophthalmology practice that specializes in treating ocular disorders, particularly glaucoma and cataracts, for Swiss and foreign patients.

Swiss Eye Centre

Cloudbreak Pharma is a clinical stage ophthalmic drug company focused on developing treatments for various ocular diseases. The company works on ocular drug research and development.

Cloudbreak Pharma

Dr. Agarwal's Eye Hospital Ltd. operates as an eye hospital, which engages in the provision of eye care solutions. Its services include operations in cataract, cornea lasik and smile, retina, orbit and oculoplasty, optical, glaucoma, uvea, neuro ophthalmology, and squint and pediatric ophthalmology. It also conducts continuous training and research and development programs. The company was founded in 1957 by Jaiveer Agarwal, Tahira Agarwal, Amar Agarwal, and Athiya Agarwal and is headquartered in Chennai, India.

Dr. Agarwal's Eye Hospital Limited

SERI Lugano is involved in research and innovation in the field of vision, offering various ophthalmic treatments and solutions. The institute also focuses on non-surgical methods for conditions such as myopia and presbyopia.

Metric
Company Name	SERI Lugano	Swiss Eye Centre	Cloudbreak Pharma	Dr. Agarwal's Eye Hospital Limited
Symbol				DRAGARWQ
MSH ID	CH:SERI-LUGANO	CH:SWISSEYECENTRE	COM:CLOUDBREAKPHARMA	COM:DRAGARWAL
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Medical & Healthcare	Medical Services	Pharmaceuticals	Medical - Care Facilities
Country	CH	CH	US	IN
Stage
Employee Count				974
Website	seri-lugano.ch	swisseyecentre.ch	cloudbreakpharma.com	dragarwal.com
LinkedIn	seri-lugano
Founders

Metric
Market Cap		182.55M
Enterprise Value
Monthly Web Traffic	1.08K
Web Traffic Growth	89.33
Valuation
Raised Capital

Metric
Revenue				37.70M
Revenue (LTM)
Revenue (NTM)
Gross Profit				12.99M
EBITDA				10.75M
Operating Income				7.61M
Net Income				5.47M
EPS				1.16
Diluted EPS				1.16
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.77
Operating Profit Margin				0.21
EBITDA Margin				0.29
Net Profit Margin				0.15
Return on Equity				0.76
Return on Assets				0.10
Return on Capital Employed				0.16

SERI

CH:SERI-LUGANO

SERI Lugano

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				30.93
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				7.66
EV Multiple				23.22

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding				33.83
Operating Cycle				48.69
Cash Conversion Cycle
Asset Turnover				0.69

Metric
Operating Cash Flow				10.68M
Free Cash Flow				2.26M
Cash Flow to Debt				0.73
Operating Cash Flow/Sales				0.15
Free Cash Flow Yield				0.03

Metric
Cash & Equivalents				3.98M
Accounts Receivable				-438.01K
Inventory				1.15M
Goodwill				21.25K
Debt to Capitalization				0.29
Debt to Assets
Current Ratio
Quick Ratio				0.62

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue				0.16